I’m very glad that I made the choice to use HUMATE-P. It worked very well for me."
For your patients who have von Willebrand disease (VWD)
Bleeding control when
they need it most
HUMATE-P provides bleed control across all VWD types, including Type 3—the most severe
“Excellent” or “Good” overall clinical response demonstrated across the majority of treatment events in a retrospective study (N=97)*2
424/437
treatment events
332/344 nonsurgical
bleeding events
72/73 surgeries
*Retrospective review of 97 Canadian patients. Excellent was defined as hemostasis achieved/complete
cessation of bleeding.
Good was defined as slight oozing/partial but adequate control of bleeding and did not require
additional product for unplanned treatment.2
*Retrospective review of 97 Canadian patients. Excellent was defined as hemostasis achieved/complete cessation of bleeding. Good was defined as slight oozing/partial but adequate control of bleeding and did not require additional product for unplanned treatment.2
Bekah’s birthing experience with HUMATE-P
I’m very glad that I made the choice to use HUMATE-P. It worked very well for me." —Bekah, HUMATE-P user
Individual patient experiences may vary.
Video Player is loading.
Bekah’s birthing experience with HUMATE-P
Video Player is loading.
—Bekah, HUMATE-P user
Individual patient experiences may vary.
Have additional questions?
Connect with CSL Behring Medical Affairs to find additional information and ask questions.
CSL Behring provides additional treatment options to support the bleeding disorder community:
Learn about a treatment that makes zero bleeds a possibility for your hemophilia B patients
Visit the Product WebsiteExplore a twice-weekly dosing option for your hemophilia A patients
Visit the Product WebsiteReferences
- Data on file. Available from CSL Behring as DOF HUM-002.
- Lillicrap D, Poon M-C, Walker I, Xie F, Schwartz BA, and members of the Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/ HUMATE-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002;87(2):224-230.